Educational Activities Archives

hotspot_textonly
Filter by Target Audience

Please select the option that best aligns with your profession.

Target Audience
hotspot_textonly
Filter by Topic

Please select the option that best aligns with your topic of interest.

Click on the plus (+) icon to display subtopics.

hotspot_textonly
Filter by Format

Please select the option that best aligns with your preferred format of training.

Formats
hotspot_textonly
Key Term Search

Use the search bar to enter in the title of a training, or other key terms.

Format: Module
Opioids are commonly prescribed for chronic pain, but are also associated with a risk for serious harms, including overdose and opioid use disorder. This course reviews risk factors for opioid misuse, opioid use disorder, and overdose in patients with chronic pain, explains methods for screening and assessing for problematic opioid use, reviews methods for mitigating risks associated with prescribed opioids, and details non-opioid treatment approaches for pain. The course is based on principles in the Center for Disease Control and Prevention’s guideline on opioids for chronic pain and reviews recent evidence on benefits and harms of opioids.
Presenter(s):
Roger Chou, MD
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Format: Module
Interactive, SCORM-based Activity
Opioid use disorder (OUD) has highly effective FDA-approved medications for its treatment. This course reviews and compares pharmacological treatment options for individuals with OUD, including methadone, buprenorphine (sublingual and injectable formulations), and naltrexone (oral and long-acting intramuscular formulations). Current evidence for each medication is reviewed in detail, and studies comparing each are discussed. The purpose and goal of medications for OUD are reviewed, and different treatment models are presented. The course includes case vignettes in which medication options for OUD are considered.
Presenter(s):
Melissa B. Weimer, DO, MCR, DFASAM
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Format: Module
Substance Use disorders in Older Adults is a growing problem not only in the United States but throughout the developed world. The Baby Boomer generation, born between 1946 and 1964 is turning 58-76 years old this year. This group is presenting with more Substance Use Disorders and need for substance use treatment now. The use of an artificial cut off age of 65 years of age as the definition of elderly or old is somewhat arbitrary and this will be discussed. The module will look at the prevalence, screening and treatment of tobacco, alcohol, opioids, non-medical use of prescription drugs and illicit opioids as well as stimulants and cocaine, marijuana and non-opioid sedative hypnotic agents. A case vignette will drive the CME portion and elucidate the tenants of the module.
Presenter(s):
Louis A. Trevisan, MD, MEd, Associate Professor, Adjunct, Yale University School of Medicine
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Format: Webinar
This webinar will explore the intersection of substance use and veteran status, examining the impact of post-traumatic stress, moral injury, and systemic barriers to care. Participants will learn about evidence-based interventions, and resources available to veterans.
Presenter(s):
Dr. Pilar Horner, MSW, PhD; Tina Thompson, MSW, LMSW; and Scott Saghy, MSW; U.S. Army veteran, social worker
Credit Available:
CE Credit(s): Yes
Designations: 1 ASWB ACE Credit
Format: Webinar
Over 2.5 million adults in the U.S. are diagnosed with OUD. In 2022, 12.7% of ED visits involved opioids. Yet only 25% of those who need treatment receive recommended MOUD. MOUDs are highly effective treatments that have been shown to decrease opioid use, cravings and transmission of infectious disease, and to increase retention in treatment. As the opioid epidemic continues to impact people across the U.S., the ED represents a critical access point to the health care system, supporting people with OUD by initiating MOUD, such as buprenorphine, and connecting them to low-threshold, easy-to-access care for continued treatment.
Presenter(s):
Arianna Campbell, DMSc, MPH, PA-C
Credit Available:
CE Credit(s): No
Certificate: Certificate of Attendance, 1-hour
Format: Webinar
Due to the opioid epidemic, over 2.5 million adults in the U.S. have opioid use disorder (OUD), yet only 25% of those who need treatment receive recommended medication for opioid use disorder (MOUD). Alongside the rising rates of OUD, there has been an increase in infectious diseases such as HIV, hepatitis B and C, endocarditis and skin and soft-tissue infections, particularly among people who inject drugs. These intertwining epidemics have not been sufficiently addressed, but MOUD — combined with appropriate substance use treatment supports and health care services — represents an opportunity to reduce risk and improve health outcomes.
Presenter(s):
Daniel Rosa, MD
Credit Available:
CE Credit(s): No
Certificate: Certificate of Attendance, 1-hour